Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01877668 · ClinicalTrials.gov registry record · Phase 3
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 422
- Enrollment target
NCT01877668 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 422 participants.
The verdict
NCT01877668, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 422 participants
- Enrollment target
Study Summary
This is a 12-month study investigating the effectiveness and safety of tofactinib in treating the signs and symptoms of active psoriatic arthritis and improving physical function and preserving bone structure in patients with an inadequate response to a traditional, nonbiologic disease-modifying antirheumatic drug. Adalimumab is used as a comparator.
Interventions
- DRUG Placebo
- DRUG Adalimumab
- DRUG Tofacitinib 5 mg BID
- DRUG Tofacitinib 10 mg BID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 422 participants |
| Start Date | 2014-01-20 |
| Est. Completion | 2015-12-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01877668
The ClinicalTrials.gov registry entry for NCT01877668 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 422 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01877668 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01877668 about?
NCT01877668 is a clinical study titled "Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study". This is a 12-month study investigating the effectiveness and safety of tofactinib in treating the signs and symptoms of active psoriatic arthritis and improving physical function and preserving bone structure in patients with an inadequate response to a traditional, nonbiologic disease-modifying ant...
What is the current status of trial NCT01877668?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 422 participants. The study started on 2014-01-20. Estimated completion is 2015-12-18.
What interventions are being tested in trial NCT01877668?
The interventions under investigation include: Placebo (DRUG), Adalimumab (DRUG), Tofacitinib 5 mg BID (DRUG), Tofacitinib 10 mg BID (DRUG).
Who is sponsoring clinical trial NCT01877668?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.